Link:Presentation of Maria José Vidal

Research on Digestive and
Liver Diseases in FP7
Maria José Vidal-Ragout, MD, PhD
Head of Unit, Medical Research
Directorate-General for Research & Innovation
European Commission
1. EU
digestive and liver disease's
research: How does it work?
2. What
3. The
has been addressed?
future: Horizon 2020
Strategic objectives for research on
digestive and liver diseases
Provide evidence-based solutions
for clinical challenges and develop
preventive approaches
Address common risk factors (e.g.
obesity, alcohol, infection,
lifestyle, etc.) and identify
vulnerable populations
Foster improved diagnosis, early
detection and stratified therapies
Provide proof-of-concept for the
establishment of integrated care
EU research
on digestive
and liver
ERC, People
EU digestive and liver
diseases 'research
Schemes and funds
(in Million Euro)
EU digestive and liver
diseases’ research
What’s being funded
 development of new therapies
 Large-scale genetic studies
 mechanistic and animal model
 computer simulation of digestive
 Stem cells research and artificial
 mathematical modelling of cell
proliferation and tissue
organization in tumours
 molecular analysis of hepatitis virus
 development of imaging tools
 IT applications for patient support
 comorbidities
 training and mobility programmes
€ 382,8 million on research on digestive and liver diseases
EU health research delivers
results to patients
The Use of Methylated DNA Immunoprecipitation (MeDIP) in
Cancer for better Clinical Management
Altered epigenetic status:
prognostic markers for colon
cancer patients
DNA methylation kits for clinical
analyses of liver and colon cancers
Role of inflammation in tumour initiation
and progression
EU health research
concentrates scarce
Prognostic markers for GIST patients
EU health research fosters evidencebased best clinical care
EU health research contributes to tailor
treatment to individual patients
From ethiopatogenetic insight
into innovative therapy
7 academic partners, 2 SMEs
5 years
€ 2.9 million
Start date: March 2008
Public Private Partnerships: –
the Innovative Medicines
MIP-DILI: Mechanism-Based Integrated Systems for the
Prediction of Drug-Induced Liver Injury
 Develop models that take into
account the natural differences
between patients
 Evidence-based evaluation of both
currently available and new
laboratory test systems
10 academic partners, 6 SMEs,
11EFPIA partners
5 years
€ 32.4 million
Start date: February 2012
Challenges in research on digestive and liver diseases
© pixologic, #43498499, 2012.
Source :
Better prevention
Novel biomarkers for disease
Investigator-driven CTs
Stratified patient populations and
targeted therapies
Innovative technology and devices
Increased incidence of lifestyle
associated diseases, e.g. alcohol
Co-morbidity, e.g. ageing, obesity,
Patient-reported outcomes
Improvements still need to be made…
EU research budget
represents only ~ 5% of
research expenditure in MS
Low coordination, Cancer
invest less than
in the US
and liver
Towards joint programming in research Working together to tackle common challenges more effectively, EU COM (2008) 468
To address significant challenges…
• Increasing pressure on European healthcare
• Raising costs
• Over-utilisation of care, differences in
outcomes, rapid expansion and shortening life
cycles of technologies and insufficient
comparative assessment of current practices
and approaches
…and benefit from opportunities
• Stratified and subsequently personalised
medicine can deliver cost savings and better
outcomes for patients
• But the building blocks are many and linked,
requiring clinical trials, a better understanding
of disease and comorbidity, and efforts to
translate results to the clinic
Horizon 2020: The next Framework
Programme for research and innovation
Proposed budget: €80bn, a 46% increase compared to FP7
Europe needs cutting edge research and innovation
Essential to ensure competitiveness, growth and jobs
Vital to tackle pressing societal challenges
3% of GDP invested in R&D: headline target of Europe 2020
Horizon 2020 novelties
• Simplification:
Simpler programme architecture, a single
set of rules
Easy to use cost reimbursement model: one
project - one funding rate
Less paperwork in preparing proposals
Reduce time to grant by 100 days
• Inclusive approach:
More support for innovation and activities
close to the market
Strong focus on creating business
New SBIR-like scheme dedicated to SMEs
• Renewed successful partnerships:
Horizon 2020: Health, Demographic Change
and Wellbeing Challenge Proposal: ~ €8.5bn
Understanding the determinants of
health (including environmental and climate
related factors), improving health promotion
and disease prevention;
• Treating disease
Transferring knowledge to clinical practice
and scalable innovation actions
Developing effective screening
programmes and improving the
assessment of disease susceptibility
Better use of health data
Improving scientific tools and methods to support
policy making and regulatory needs
Active ageing, independent and assisted living
• Understanding disease
Individual empowerment for self-management of
Promoting integrated care
Optimising the efficiency and effectiveness
of healthcare systems and reducing
inequalities through evidence based decision
making and dissemination of best practice, and
innovative technologies and approaches.
Improving surveillance and preparedness
Developing better preventive vaccines
• Improving diagnosis
Using in-silico medicine for improving
disease management and prediction
Horizon 2020: Health Challenge:
Some of the key features
Adapting to an ageing population
Pursuing the path to more personalised medicine
Translational research (clinical trials)
Harnessing and encouraging private sector capability
Coordinating national efforts
Reducing costs (comparative effectiveness research)
Expanding global cooperation
Thank you!
EU health research delivers
results to patients
Role of inflammation in tumour initiation
and progression
Prognostic marker for GIST patients
5H2TB inhibitor reduces liver fibrosis

similar documents